Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PTPRC | P08575 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.58 |
| ▸ | S100A4 | P26447 | 2/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MPI | P34949 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16559365 | 0.92 | MAPT (0.61) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL13765164 | 0.90 | PTPRC (0.58) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL27931452 | 0.88 | PTPRC (0.54) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL12298162 | 0.84 | PTPRC (0.58) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL16559359 | 0.84 | MAPT (0.52) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL1527540 | 0.81 | PTPRC (0.54) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL31456586 | 0.81 | PTPRC (0.54) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL4053805 | 0.81 | MAPT (0.49) | MAPTRAB9ASMN1; SMN2CASP3SENP8 | |
| SCHEMBL30954730 | 0.80 | BAZ1A (0.58) | MAPTRAB9ASMN1; SMN2CASP3ALDH1A1 | |
| SCHEMBL568785 | 0.80 | BAZ1A (0.58) | MAPTRAB9ASMN1; SMN2CASP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-6933314-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040077693-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6706753-B2 | 2-AMINO-FLUORENE DERIVATIVES USEFUL FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH ALPHA 4 INTERGRINS OR THEIR LIGANDS | GENENTECH, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | GENENTECH, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| US-6008411-A | THE ANTIBODIES AND ENZYME CONJUGATES ARE PROVIDED IN COMBINATION IN KITS TO BE USED FOR THE RAPID AND ACCURATE DETERMINATION OF NORTRIPTYLINE IN SERUM AND OTHER BODILY FLUIDS; A TRICYCLIC ANTIDEPRESSANT | DADE BEHRING MARBURG GMBH (DE) | 1999-12-28 | — | — | US | disclosed |
| EP-0177344-B1 | SERUM PRETREATMENT FOR TRICYCLIC ANTIDEPRESSANT DRUG ASSAYS AND KIT THEREFOR | SYNTEX (U.S.A.) INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0167256-B1 | NORTRIPTYLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, CONJUGATES THEREOF TO ANTIGENIC PROTEINS AND ENZYMES, ANTIBODIES THERETO, AND RELATED ASSAY METHODS | SYNTEX (U.S.A.) INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| US-4795822-A | ANTIDEPRESSANT | SYNTEX (U.S.A.) INC. (US) | 1989-01-03 | — | — | US | disclosed |
| EP-0177344-A2 | Serum pretreatment for tricyclic antidepressant drug assays and kit therefor | SYNTEX (U.S.A.) INC. (US) | 1986-04-09 | — | — | EP | disclosed |
| EP-0167256-A1 | Nortriptyline derivatives, processes for their preparation, conjugates thereof to antigenic proteins and enzymes, antibodies thereto, and related assay methods | SYNTEX (U.S.A.) INC. (US) | 1986-01-08 | — | — | EP | disclosed |
| US-4003915-A | ANTICONVULSANTS, PARKINSON*S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077693-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | MAPT 4730/4885RAB9A 879/4885SMN1; SMN2 3119/4885 |
| US-20020035104-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | MAPT 4730/4885RAB9A 879/4885SMN1; SMN2 3119/4885 |
| US-20050187284-A1 | Integrin receptor inhibitors | ITGA4, ITGB4, ITGB1 | MAPT 4495/4885RAB9A 700/4885SMN1; SMN2 3338/4885 |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | ITGA1, ITGA2, ITGB1 | MAPT 4867/4885RAB9A 1287/4885SMN1; SMN2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.